Shaanxi Xiyue Pharmaceutical Co Ltd.

Using doxycycline hydrochloride tablets (0.1 g) from Shaanxi Xiyue Pharmaceutical Co., Ltd. as the test formulation and doxycycline hydrochloride tablets (Vibramycin®, 100 mg) from Pfizer Japan Inc. as the reference formulation, the pharmacokinetic parameters and relative bioavailability of the two formulations under fasting single-dose administration were investigated to evaluate whether the two formulations were bioequivalent; and the safety of doxycycline hydrochloride tablets in healthy trial participants was evaluated.

Primary objective: To investigate the pharmacokinetic parameters and relative bioavailability of celecoxib capsules (0.2 g) manufactured by Shaanxi Xiyue Pharmaceutical Co., Ltd. as the test formulation and celecoxib capsules (trade name: Celebrex®, 0.2 g) manufactured by Viatris Pharmaceuticals LLC as the reference formulation after a single postprandial dose, and to evaluate the bioequivalence of the two formulations. Secondary objective: To evaluate the safety of single postprandial oral administration of celecoxib capsules (test and reference formulations) in participants of the Chinese Health Study.

Primary objective: To investigate the pharmacokinetic parameters and relative bioavailability of celecoxib capsules (0.2 g) manufactured by Shaanxi Xiyue Pharmaceutical Co., Ltd. as the test formulation and celecoxib capsules (trade name: Celebrex®, 0.2 g) manufactured by Viatris Pharmaceuticals LLC as the reference formulation after a single fasting administration, and to evaluate the bioequivalence of the two formulations. Secondary objective: To evaluate the safety of a single fasting oral administration of celecoxib capsules (test and reference formulations) to participants in the Chinese Health Study.